Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1994-03-10
1996-01-16
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
424 59, 424 701, 424401, 514844, 514845, 514846, 514847, 514848, 514861, 514863, 514864, 514880, A61K 700, A61K 740, A61K 748
Patent
active
054848164
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an external skin treatment composition in which the stability of vitamin A is extremely improved.
BACKGROUND ART
It has been well known that vitamin A is effective for prevention or treatment of keratodermatitis and, prevention of and recovery from dermal aging.
Vitamin A, however, is structurally very unstable and can readily cause isomerization, decomposition, polymerization, etc., with light, air, heat, metal ion, etc. Thus, it has been difficult to stably formulate vitamin A into an external skin treatment composition.
SUMMARY OF THE INVENTION
Accordingly, the present invention relates to an external skin treatment composition in which the stability of vitamin A is extremely improved by formulating a stabilizer for improving the stability of vitamin A.
In accordance with the present invention, there is provided an external skin treatment composition comprising (I) vitamin A and (II) at least one stabilizer selected from the group consisting of (1) chelating agents and polysaccharides, (2) oils having an iodine value of 70 or more, (3) polyethylene glycol and/or polypropylene glycol, (4) hydroxy carboxylates, (5) neutral amino acids, (6) (i) at least one oil-soluble antioxidant selected from the group consisting of butyl hydroxytoluene, butyl hydroxyanisole, .alpha.,.beta.,.gamma.,.delta.-tocopherol, nordihydrogualaretin, propyl gallate, fatty acid esters of vitamin C and sorbic acid, (ii) at least one ethylenediaminetetraacetate and (iii) at least one benzophenone compound, (7) (i) at least one oil-soluble antioxidant selected from the group consisting of butyl hydroxytoluene, butyl hydroxyanisole, .alpha.,.beta.,.gamma.,.delta.-tocopherols, nordihydrogualaretin, propyl gallate and fatty acid esters of vitamin C, (ii) at least one compound selected from the group consisting of ascorbic acid, ascorbic acid salt, isoascorbic acid, isoascorbic acid salt, sorbic acid and sorbic acid salt and (iii) at least one benzophenone compound, (8) inclusion compounds of cyclodextrins including antioxidants and/or ultraviolet absorbers, (9) at least one kind of butanediol and/or at least one oil-soluble antioxidant, (10) at least one water-soluble benzophenone compound, (11) at least one compound selected from the group consisting of basic amino acids and the salts thereof, (12) at least one compound selected from the group consisting of acidic amino acids and the salts thereof, (13) at least one polar oil selected from the group consisting of pentaerythritol fatty acid esters and trimethylolpropane fatty acid esters, and (14) at least one water-swellable clay mineral.
BEST MODE FOR CARRYING OUT THE INVENTION
In consideration of the above circumstances, the present inventors have conducted extensive study and research efforts. As a result, it has been found that the stability of vitamin A is extremely improved by formulating the specified stabilizer therein. Thus the present invention has been achieved.
The present invention will be described in detail below.
As vitamin A used in the present invention, vitamin A (also called retinol), all-trans type vitamin A or 13-cis type vitamin A is desirable. A mixture thereof can also be used.
The amount of vitamin A to be formulated into the external skin treatment composition according to the present invention is not particularly limited. However, if the effect on the skin as a function of vitamin A is taking into consideration, the amount is 0.0001% by weight or more, based upon the total weight of the composition. If further effects of vitamin A are required, 0.001% by weight or more of the same is preferably used. The upper limit of the formulation amount is preferably 1% by weight in view of the properties as an external skin treatment composition.
According to the first embodiment of the present invention, as a stabilizer, the combination of a chelating agent and a polysaccharide is used.
As a chelating agent used in the present invention, mention may be made of inorganic alkali salts of ethylenediaminetetraacetat
REFERENCES:
patent: Re33845 (1992-03-01), Schreuder
patent: 4011313 (1977-03-01), Thompson
patent: 4154823 (1979-05-01), Schutt
patent: 4248861 (1981-02-01), Schutt
patent: 4333924 (1982-06-01), Bowley et al.
patent: 4454159 (1984-06-01), Musher
patent: 4464394 (1984-08-01), Bollag
patent: 4481186 (1984-11-01), Deckner
patent: 4505902 (1985-03-01), Millard
patent: 4603046 (1986-07-01), Georgalas et al.
patent: 4604281 (1986-08-01), Deckner et al.
patent: 4695452 (1987-09-01), Gannis et al.
patent: 4740432 (1988-04-01), Bosserelle
patent: 4742066 (1988-05-01), Deckner et al.
patent: 4764505 (1988-08-01), Fujinuma et al.
patent: 4769234 (1988-09-01), Pines et al.
patent: 4783332 (1988-11-01), Schreuder
patent: 4847267 (1989-07-01), Deckner et al.
patent: 4863970 (1989-09-01), Patel et al.
patent: 4882359 (1989-11-01), Nakagawa et al.
patent: 4906457 (1990-03-01), Ryan
patent: 4938960 (1990-07-01), Ismail
patent: 4948577 (1990-08-01), Hara
patent: 4970216 (1990-11-01), Deckner et al.
patent: 4978523 (1990-12-01), Motegi et al.
patent: 4985455 (1991-01-01), Motono
patent: 5000937 (1991-03-01), Grollier et al.
patent: 5037850 (1991-08-01), Elliott et al.
patent: 5061480 (1991-10-01), Marchese et al.
patent: 5082661 (1992-01-01), Melnik et al.
patent: 5093511 (1992-03-01), Yoshida et al.
patent: 5135913 (1992-08-01), Pickart
patent: 5137725 (1992-08-01), Handjani et al.
patent: 5173301 (1992-12-01), Itoh et al.
patent: 5213799 (1993-05-01), Goring et al.
patent: 5244665 (1993-09-01), Natraj et al.
patent: 5268180 (1993-12-01), Morancais et al.
patent: 5281196 (1994-01-01), Sultenfuss
patent: 5298528 (1994-03-01), Evers
patent: 5310730 (1994-05-01), Fujinuma et al.
patent: 5348943 (1994-09-01), Pickart
Edward Sagarin, "Cosmetics Science and Technology", Interscience Publishers division of John Wiley & Sons, N.Y., N.Y., third printing May 1966, pp. 115-117, 168, 169, 465, 466, 506, 507, 858-863, 1034, 1035, 1063-1070, 1111-1113, 1134, 1135 & 1155.
Susan Budavari, "The Merck Index, eleventh edition", published by Merck & Co., Inc., Rahway, N.J., 1989, p. 1576, entry 9918.
JP-A-64-40412, Published Feb. 10, 1989.
JP-A-63-258807, Published Oct. 26, 1988.
JP-A-2-502546 (WO 89/05642 derived from PCT/US88/04539), Published Aug. 16, 1990.
Sakamoto Okihiko
Yanagida Takeshi
Griffin Ronald W.
Shiseido Company Ltd.
LandOfFree
External skin treatment composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with External skin treatment composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and External skin treatment composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-309719